Search research articles
Contact Us
Filters
Showing results (31-40 of 53) with videos related to
Page
of 6
Sort By:
Lancet (London, England)
|
July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Paul E Sax, Edwin DeJesus, Anthony Mills, et al.
The Patient
|
May 31, 2021
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)
Vasiliki Chounta, Edgar T Overton, Anthony Mills, et al.
Lancet (London, England)
|
September 5, 2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Joel Gallant, Adriano Lazzarin, Anthony Mills, et al.
AIDS (London, England)
|
October 15, 2021
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
Anthony Mills, Gary J Richmond, Cheryl Newman, et al.
Respiratory Investigation
|
September 10, 2024
Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial
David Fitz-Patrick, Hanako Mihara, Anthony Mills, et al.
AIDS and Behavior
|
May 25, 2020
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
Miranda Murray, Antonio Antela, Anthony Mills, et al.
The Journal of Infectious Diseases
|
January 22, 2014
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
Antonella Castagna, Franco Maggiolo, Giovanni Penco, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 14, 2015
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study
Anthony Mills, Gordon Crofoot, Cheryl McDonald, et al.
The Lancet. HIV
|
February 2, 2024
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study
Joseph J Eron, Susan J Little, Gordon Crofoot, et al.
The Lancet. HIV
|
March 6, 2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 53) with videos related to
Sort By:
Page
of 6
Lancet (London, England)
|
July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Paul E Sax, Edwin DeJesus, Anthony Mills, et al.
The Patient
|
May 31, 2021
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)
Vasiliki Chounta, Edgar T Overton, Anthony Mills, et al.
Lancet (London, England)
|
September 5, 2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Joel Gallant, Adriano Lazzarin, Anthony Mills, et al.
AIDS (London, England)
|
October 15, 2021
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
Anthony Mills, Gary J Richmond, Cheryl Newman, et al.
Respiratory Investigation
|
September 10, 2024
Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial
David Fitz-Patrick, Hanako Mihara, Anthony Mills, et al.
AIDS and Behavior
|
May 25, 2020
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
Miranda Murray, Antonio Antela, Anthony Mills, et al.
The Journal of Infectious Diseases
|
January 22, 2014
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
Antonella Castagna, Franco Maggiolo, Giovanni Penco, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 14, 2015
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study
Anthony Mills, Gordon Crofoot, Cheryl McDonald, et al.
The Lancet. HIV
|
February 2, 2024
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study
Joseph J Eron, Susan J Little, Gordon Crofoot, et al.
The Lancet. HIV
|
March 6, 2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, et al.
Page
of 6